Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PHVS NASDAQ:PRAX NASDAQ:SYRE NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePHVSPharvaris$34.71+2.1%$30.68$16.72▼$35.33$2.22B-2.35346,038 shs725,457 shsPRAXPraxis Precision Medicines$350.56+6.9%$314.63$37.19▼$366.52$9.14B2.71679,052 shs698,949 shsSYRESpyre Therapeutics$90.16+2.6%$76.83$14.00▼$102.06$7.63B3.051.72 million shs1.99 million shsTGTXTG Therapeutics$55.72-0.2%$42.62$25.28▼$57.38$8.55B1.683.00 million shs2.14 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePHVSPharvaris+2.06%+5.18%+15.09%+22.87%+104.18%PRAXPraxis Precision Medicines+6.95%+15.55%+0.17%+8.81%+715.26%SYRESpyre Therapeutics+2.58%-10.13%+22.67%+78.75%+492.38%TGTXTG Therapeutics-0.20%+2.43%+46.86%+67.73%+51.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePHVSPharvaris$34.71+2.1%$30.68$16.72▼$35.33$2.22B-2.35346,038 shs725,457 shsPRAXPraxis Precision Medicines$350.56+6.9%$314.63$37.19▼$366.52$9.14B2.71679,052 shs698,949 shsSYRESpyre Therapeutics$90.16+2.6%$76.83$14.00▼$102.06$7.63B3.051.72 million shs1.99 million shsTGTXTG Therapeutics$55.72-0.2%$42.62$25.28▼$57.38$8.55B1.683.00 million shs2.14 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePHVSPharvaris+2.06%+5.18%+15.09%+22.87%+104.18%PRAXPraxis Precision Medicines+6.95%+15.55%+0.17%+8.81%+715.26%SYRESpyre Therapeutics+2.58%-10.13%+22.67%+78.75%+492.38%TGTXTG Therapeutics-0.20%+2.43%+46.86%+67.73%+51.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePHVSPharvaris 2.69Moderate Buy$49.6443.00% UpsidePRAXPraxis Precision Medicines 2.95Moderate Buy$569.6362.49% UpsideSYRESpyre Therapeutics 3.00Buy$95.836.29% UpsideTGTXTG Therapeutics 2.75Moderate Buy$58.605.17% UpsideCurrent Analyst Ratings BreakdownLatest PHVS, PRAX, SYRE, and TGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026PRAXPraxis Precision Medicines Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$537.00 ➝ $575.006/25/2026PHVSPharvaris Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$41.00 ➝ $46.006/23/2026SYRESpyre Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$115.00 ➝ $135.006/22/2026TGTXTG Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$83.006/17/2026PRAXPraxis Precision Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$449.006/17/2026PRAXPraxis Precision Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy6/16/2026SYRESpyre Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$100.006/16/2026PHVSPharvaris HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/15/2026SYRESpyre Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$98.00 ➝ $112.006/4/2026SYRESpyre Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/4/2026SYRESpyre Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$102.00 ➝ $115.00(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPHVSPharvarisN/AN/AN/AN/A$4.71 per shareN/APRAXPraxis Precision MedicinesN/AN/AN/AN/A$34.85 per shareN/ASYRESpyre Therapeutics$890K8,797.18N/AN/A$7.21 per share12.50TGTXTG Therapeutics$616.29M13.84$2.80 per share19.92$4.08 per share13.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePHVSPharvaris-$198.79M-$3.18N/AN/AN/AN/A-67.56%-61.13%8/11/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)SYRESpyre Therapeutics-$155.20M-$2.08N/AN/AN/AN/A-42.88%-27.76%8/4/2026 (Estimated)TGTXTG Therapeutics$447.18M$2.8619.4820.26N/A65.95%88.73%43.44%8/3/2026 (Estimated)Latest PHVS, PRAX, SYRE, and TGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026PHVSPharvaris-$0.8219-$0.70+$0.1219-$0.69N/AN/A5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/6/2026Q1 2026TGTXTG Therapeutics$0.23$0.12-$0.11$0.12$200.33 million$204.92 million5/5/2026Q1 2026SYRESpyre Therapeutics-$0.66-$0.74-$0.08-$0.74$70.87 millionN/A4/3/2026Q4 2025PHVSPharvaris-$0.69-$0.84-$0.15-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthPHVSPharvarisN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPHVSPharvarisN/A11.2411.24PRAXPraxis Precision MedicinesN/A15.8815.88SYRESpyre TherapeuticsN/A8.978.97TGTXTG Therapeutics1.285.815.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPHVSPharvarisN/APRAXPraxis Precision Medicines67.84%SYRESpyre Therapeutics80.39%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipPHVSPharvarisN/APRAXPraxis Precision Medicines3.00%SYRESpyre Therapeutics15.69%TGTXTG Therapeutics8.87%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePHVSPharvaris3065.41 millionN/ANot OptionablePRAXPraxis Precision Medicines11027.88 million27.04 millionOptionableSYRESpyre Therapeutics7386.84 million73.22 millionOptionableTGTXTG Therapeutics290153.08 million139.51 millionOptionablePHVS, PRAX, SYRE, and TGTX HeadlinesRecent News About These CompaniesTG Therapeutics Surged 88%: Time To Be More Careful (Rating Downgrade)June 29 at 12:30 PM | seekingalpha.comIs TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?June 19, 2026 | insidermonkey.comIs TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?June 19, 2026 | finance.yahoo.comTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Moderate Buy" from BrokeragesJune 19, 2026 | americanbankingnews.comTG Therapeutics Stock Rises Thursday: What's Driving The Gains?June 18, 2026 | benzinga.comTGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical DataJune 17, 2026 | msn.comTG Therapeutics stock is on a hot streak: Why it's up 70% and climbingJune 17, 2026 | msn.comTG Therapeutics, Inc. $TGTX Shares Sold by WINTON GROUP LtdJune 11, 2026 | marketbeat.comTG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?June 11, 2026 | zacks.comWhy TG Therapeutics (TGTX) Is Up 18.4% After Advancing At‑Home Subcutaneous BRIUMVI In MS TreatmentJune 10, 2026 | finance.yahoo.comTGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MGJune 10, 2026 | zacks.comTGTX Stock Jumps 5% On Positive Early Data For At-Home BRIUMVI In Muscle DiseaseJune 10, 2026 | finance.yahoo.comTG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comTG Thera posts early-stage data for Briumvi in myasthenia gravis; launches mid-stage trialJune 9, 2026 | seekingalpha.comTG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized ...June 9, 2026 | finance.yahoo.comA Look At TG Therapeutics (TGTX) Valuation After Recent Positive BRIUMVI Trial UpdatesJune 9, 2026 | finance.yahoo.comTG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 TrialJune 9, 2026 | globenewswire.comB. Riley Securities Remains a Buy on TG Therapeutics (TGTX)June 8, 2026 | theglobeandmail.comWhy Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?June 5, 2026 | zacks.comTG Therapeutics rises on early-stage trial data for Briumvi injectableJune 4, 2026 | seekingalpha.comTGTX Stock Applies Brakes On 5-Session Losing Streak – Retail Eyes ‘Multi-Billion’ Sales As At-Home Multiple Sclerosis Treatment Gets BoostJune 4, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHVS, PRAX, SYRE, and TGTX Company DescriptionsPharvaris NASDAQ:PHVS$34.71 +0.70 (+2.06%) Closing price 06/29/2026 04:00 PM EasternExtended Trading$34.66 -0.05 (-0.13%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Praxis Precision Medicines NASDAQ:PRAX$350.56 +22.77 (+6.95%) Closing price 06/29/2026 04:00 PM EasternExtended Trading$313.26 -37.30 (-10.64%) As of 06:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Spyre Therapeutics NASDAQ:SYRE$90.16 +2.27 (+2.58%) Closing price 06/29/2026 04:00 PM EasternExtended Trading$90.37 +0.21 (+0.24%) As of 06:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.TG Therapeutics NASDAQ:TGTX$55.72 -0.11 (-0.20%) Closing price 06/29/2026 04:00 PM EasternExtended Trading$55.45 -0.27 (-0.48%) As of 04:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
